ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1716

MHC Class I and Class II Genes Influence Systemic Sclerosis Susceptibility, Clinical Presentation and Autoantibody Profile in a Mexican Admixed Population

Tatiana Sofia Rodriguez-Reyna1, Joaquin Zuniga2, Julio Granados3, Pamela Mercado Velazquez4, Carlos Nunez Alvarez4, Neng Yu5, Sharon Alosco6, Alfredo Cruz Lagunas7 and Edmond Yunis8, 1Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 2Immunology, Instituo Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Mexico, Mexico, 3Transplantation, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubira, Mexico, Mexico, 4Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico, 5HLA laboratory, the American Red Cross Northeast division, American Red Cross Blood Services - Northeast Division, Dedham, MA, 6HLA Laboratory, American Red Cross Blood Services - Northeast Division, Dedham, MA, 7Immunology, Instituto Nacional de Enfermedades Respiratorias, Mexico, Mexico, 8Department of Cancer Immunology and AIDS, Dana Farber Cancer Institue, Boston, MA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: genetics and systemic sclerosis, Immunogenetics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose: Systemic Sclerosis (SSc) exhibits great clinical and serologic variability in different populations. Herein we determined MHC class I and II alleles and extended haplotypes in a cohort of Mexican SSc patients to evaluate the contribution of these loci to SSc susceptibility, clinical and autoantibody profile, and to determine the prevalence of Amerindian, Caucasian and African haplotypes.

Methods We included 159 SSc patients (ACR or LeRoy-Medsger criteria), with homogeneous ancestry (at least 3 generations). Patients were classified in diffuse cutaneous (dcSSc) and limited cutaneous systemic sclerosis (lcSSc) based on the extent of their skin involvement. They were evaluated to determine presence and severity of organ involvement (Medsger’s severity scale). Peripheral venous blood was obtained to test for ANA, SSc-associated antibodies and sequence based MHC class I and II typing. We included 234 healthy, ethnically matched individuals as controls. Admixture estimations and principal component analysis (PCA) were performed. IRB approval was obtained for this study, which was performed according to the Helsinki Declaration contents; informed consent was obtained for every participant. Differences were evaluated using Student’s t test, X2, Fisher exact test and Bonferroni when appropriate, p values <0.05 were considered significant.

Results: We found female predominance (98% vs 84%; p=0.004) and longer disease duration in lcSSc patients (13 vs 8 years; p=0.001); higher proportion of interstitial lung disease (44 vs 24%, p=0.01) and gastrointestinal involvement (73 vs 57%, p=0.03) in dcSSc patients. Anti-Topoisomerase I antibody predominated in dcSSc patients (p=0.0009), and anticentromere (ACA) in lcSSc patients (p=0.005). HLA allele analysis showed increased frequency of HLA-B*08:01 in SSc (gene frequency (gf) 4%) and in dcSSc (gf=4%) patients when compared to controls (gf=0.6%; p=0.01, OR 7.1, 95%CI 2-31; and p=0.004, OR 7.5, 95%CI 1.6-47, respectively); increased frequency of HLA-DRB1*11:04 in dcSSc patients (gf=7.8%) when compared to controls (gf=1.7%, p=0.01, OR 4.8, 95%CI 1.6-14-5); decreased frequency of HLA-DQB1*03:01 in SSc (gf=14.5%) and in lcSSc patients (gf=12.7%) when compared to controls (gf=24.7%, p=0.008, OR 0.5, 95%CI 0.3-0.7; and p=0.009, OR 0.4, 95%CI 0.2-0.7, respectively). Antibody analysis revealed association of HLA-DRB1*08:02 and HLA-DQB1*0402 alleles with anti-Topoisomerase I antibody (p=0.03, OR 2.2, 95%CI 1.2-4; and p=0.00001, OR 5.3, 95%CI 2.8-10, respectively), and HLA-DQB1*0302 was negatively associated to the presence of this autoantibody (p=0.04, OR 0.34, 95%CI 0.15-0.71). Admixture estimations using HLA-B showed significant increase in the percentage of Caucasian genes (33% in lcSSc vs 23% in dcSSc) and reduced percentage of African genes in lcSSc patients (13% vs 24% in dcSSc)

Conclusion: MHC Class I and II genes contribute to Systemic Sclerosis susceptibility, influence clinical presentation and autoantibody profile. Genetic admixture shows different components in dcSSc and lcSSc subsets and in controls.


Disclosure:

T. S. Rodriguez-Reyna,
None;

J. Zuniga,
None;

J. Granados,
None;

P. Mercado Velazquez,
None;

C. Nunez Alvarez,
None;

N. Yu,
None;

S. Alosco,
None;

A. Cruz Lagunas,
None;

E. Yunis,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mhc-class-i-and-class-ii-genes-influence-systemic-sclerosis-susceptibility-clinical-presentation-and-autoantibody-profile-in-a-mexican-admixed-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology